Sign Out
FASENRA is indicated as an add-on maintenance treatment in adult patients from 18 years with severe eosinophilic asthma characterised by the following criteria: At least two exacerbations in the past 12 months on the current standard therapy (high-dose inhaled corticosteroids plus long-acting bronchodilators) and/or need for treatment with systemic corticosteroids.
Eosinophil count in the blood of ≥0.3 G/L (corresponding to ≥300 cells/μL).
For detailed information about the patient populations investigated in trials, see Pharmacology: Pharmacodynamics: Clinical efficacy under Actions.
